title: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
abstract: OBJECTIVE
  To evaluate efficacy, safety, and quality of life (QOL) changes with epoetin alfa therapy for anemia in patients with nonmyeloid malignancies.
  
  
  METHODS
  Anemic cancer patients were enrolled onto this prospective, open-label study from 34 centers across Canada. The trial had two cohorts: patients who were and were not receiving chemotherapy during the 16-week study. All patients initially received epoetin alfa 150 IU/kg subcutaneously three times per week. The dose was doubled after 4 weeks for patients who did not experience sufficient response.
  
  
  RESULTS
  Of the 183 patients enrolled in the nonchemotherapy cohort, statistically significant and clinically relevant improvements in QOL were observed with epoetin alfa therapy using both the FACT-An questionnaire and linear analog scale assessment. Hemoglobin levels increased significantly (P <.001; mean increase 2.5 g/dL from baseline to end of study) and these increases were positively correlated with improved QOL and change in Eastern Cooperative Oncology Group (ECOG) scores. There was a significant reduction in the percentage of patients who required blood transfusions. The 218 patients in the chemotherapy cohort also experienced significant improvements in QOL, decreased transfusion use, and increased hemoglobin levels that correlated with QOL improvements and change in ECOG scores. Epoetin alfa was well-tolerated in both cohorts.
  
  
  CONCLUSIONS
  Epoetin alfa administered to patients with cancer-related anemia for up to 16 weeks resulted in significantly improved QOL, increased hemoglobin levels, and decreased transfusion use. These benefits were observed in cancer patients who were not receiving chemotherapy as well as those who were.
authors.affiliation: Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada. ian.quirt@uhn.on.ca
authors.forename: I
authors.initials: I
authors.lastname: Quirt
authors.forename: C
authors.initials: C
authors.lastname: Robeson
authors.forename: C Y
authors.initials: CY
authors.lastname: Lau
authors.forename: M
authors.initials: M
authors.lastname: Kovacs
authors.forename: S
authors.initials: S
authors.lastname: Burdette-Radoux
authors.forename: S
authors.initials: S
authors.lastname: Dolan
authors.forename: S C
authors.initials: SC
authors.lastname: Tang
authors.forename: M
authors.initials: M
authors.lastname: McKenzie
authors.forename: F
authors.initials: F
authors.lastname: Couture
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006305:Health Status Indicators; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D011446:Prospective Studies; D011788:Quality of Life; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa